China Addresses Fentanyl Accusations in Recent White Paper
China has issued a white paper opposing accusations regarding fentanyl-related substances and highlights its cooperation with the U.S. on the issue. The white paper claims that collaborative efforts have led to significant results. This announcement coincides with Former President Trump’s decision to increase tariffs on Chinese imports due to concerns over fentanyl shipments.
BEIJING (Reuters) – In a recently released white paper, China has expressed its opposition to the allegations regarding fentanyl-related substances and the shifting of accountability for this issue. The document highlights China’s commitment to collaborating with various nations, including the United States, in order to combat the challenges posed by fentanyl and its precursors, asserting that their joint efforts have yielded significant progress.
The announcement follows a decision by former U.S. President Donald Trump, who opted to raise tariffs on all imports from China from 10% to 20% as a form of retribution for what he deemed Beijing’s inadequate measures to curb the trafficking of fentanyl to the United States.
In summary, China has released a white paper that defends its stance against accusations related to fentanyl trafficking while emphasizing its collaborative efforts with the U.S. and other nations. The country asserts that it has made notable advancements in addressing the issue, despite recent punitive tariffs imposed by the U.S. government.
Original Source: www.usnews.com
Post Comment